Bart-Jan Kullberg has received the ZonMw Medical Inspirator prize 2019. This prize for the most inspiring collaboration between researchers and patients has been awarded both by a scientific jury and by public voting.The ZonMw Medical Inspirator prize includes a grant of €100.000 for the research proposed by Kullberg and two Lyme patients, studying chronic symptoms attributed to Lyme disease. The research team further includes the Lyme disease experts Dr Hadewych ter Hofstede and Dr Fidel Vos at Radboudumc and Sint Maartenskliniek, as well as the Department of Health Psychology at Leiden University, and the Amsterdam UMC Institute for Work and Health.
The PLEASE 5+ study will include the approximately 300 patients with chronic Lyme-associated symptoms who have been part of the previous PLEASE trial by the same Radboudumc researchers (N Engl J Med 2016). The current project will assess patients’ long-term experiences with both regular and complementary therapies, as well as the impact of their disease on quality of life and work. The role of patients in initiating, designing and executing the PLEASE 5+ study is unprecedented.
Bart-Jan Kullberg is member of theme Infectious diseases and global health.
Related news items
Nontuberculous mycobacteria and fungal co-infections Bonnie and Clyde?18 April 2019
In The European respiratory journal Jakko van Ingen and Sanne Zweijpfenning showed that 40% of patients diagnosed with nontuberculous mycobacterial pulmonary disease also meet diagnostic criteria for chronic pulmonary aspergillosis.read more
ESCMID award for groundbreaking studies on NTM disease18 April 2019
Jakko van Ingen received the ESCMID Young Investigator Award for his groundbreaking work on nontuberculous mycobacterial disease.read more
EU funded project BIOMAP led by Ellen van den Bogaard12 April 2019
Ellen van den Bogaard, theme Inflammatory diseases, leads the research on the experimental validation and functional analysis of identified biomarkers by using advanced organotypic skin models and receives a grant of €258,000.read more
Dosing anticancer drugs in patients with renal or hepatic impairment11 April 2019
Renal or hepatic impairment is a common comorbidity for patients with cancer either because of the disease itself, toxicity of previous anticancer treatments, or because of other factors affecting organ function, such as increased age.read more